<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Epithelial mesenchymal transition (EMT) may be physiological as part of embryological development, or pathological as part of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> development </plain></SENT>
<SENT sid="1" pm="."><plain>It is one of the key initiating events in the metastatic cascade </plain></SENT>
<SENT sid="2" pm="."><plain>EMT has profound effects on <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> cell invasiveness, proliferation and motility </plain></SENT>
<SENT sid="3" pm="."><plain>In the present article we aimed to review the potential role of EMT as a process to explain <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> progression and resistance to neoadjuvant therapy </plain></SENT>
<SENT sid="4" pm="."><plain>METHODS: Extensive literature searches were performed in Pubmed, EMBASE and Google Scholar databases to identify relevant articles published before March 2012 </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: There is adequate evidence to support the complex upstream signalling alterations needed for EMT to occur in <z:e sem="disease" ids="C1527249" disease_type="Neoplastic Process" abbrv="">colorectal cancers</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>Changes of EMT are likely to be found at the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> invasive front: the deepest, growing <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> margin </plain></SENT>
<SENT sid="7" pm="."><plain>Loss of E-cadherin at the cell membrane causes loss of cellular integrity, with subsequent migration of malignant cells and <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> budding </plain></SENT>
<SENT sid="8" pm="."><plain>These processes are associated with <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e> and recurrence of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>There is early evidence from a limited number of studies that resistance to neoadjuvant therapy in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> is associated with changes of EMT </plain></SENT>
<SENT sid="10" pm="."><plain>However, there is a lack of supporting evidence originating from human <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> tissues </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSIONS: Emerging evidence demonstrates that development of EMT in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> leads to an aggressive phenotype that may promote metastatic spread, and augment treatment resistance during neoadjuvant therapy </plain></SENT>
<SENT sid="12" pm="."><plain>A clearer understanding of the processes and role of EMT in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> may also highlight novel therapeutic strategies </plain></SENT>
</text></document>